In preclinical and clinical trials, VT-122 has exhibited a wide range of anti-tumor and immune modulatory activity, alone or in combination with other therapies.
The following two studies are underway.
Title: Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
Title: Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
The following study is complete.
Title: Regimen for the Treatment of Cachexia in Subjects With NSCLC (VT-122)